Prostate cancer: A dynamic illness with shifting targets Journal Article
| Authors: | Shaffer, D. R.; Scher, H. I. |
| Article Title: | Prostate cancer: A dynamic illness with shifting targets |
| Abstract: | Despite high response rates and palliative clinical benefits, androgen ablation does not cure advanced prostate cancer because of the inevitable emergence of resistant cells. Many new therapies under development for prostate cancer target pathways and molecules that contribute to the growth and survival of these cells. The rational and effective use of targeted therapies to eradicate resistant populations of tumour cells should be grounded on the premise that prostate cancer is a dynamic disease that evolves as it progresses, and that specific molecular determinants mediating sensitivity and resistance may be relevant only during specific states of the disease. Directed approaches must account for this changing dynamic so that clinical outcomes may be improved. |
| Keywords: | protein kinase b; protein expression; treatment outcome; clinical trial; review; cancer localization; cancer combination chemotherapy; cancer growth; drug efficacy; drug targeting; combined modality therapy; antineoplastic agent; cancer palliative therapy; prostate specific antigen; cell survival; protein bcl 2; metastasis; apoptosis; bortezomib; neoplasm recurrence, local; molecular dynamics; bisphosphonic acid derivative; cancer pain; immunoglobulin enhancer binding protein; antineoplastic activity; drug resistance, neoplasm; cetuximab; phosphatidylinositol 3 kinase; protein p53; cancer resistance; temsirolimus; prostate cancer; prostate-specific antigen; prostatic neoplasms; cancer vaccines; prostatectomy; acetylsalicylic acid; cancer cell; inhibitor of apoptosis protein; mitoxantrone; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; gefitinib; androgen antagonists; glucocorticoid; outcomes research; androgen receptor; bicalutamide; receptors, androgen; arf protein; trastuzumab; stroma cell; clinical trials; protein mdm2; atrasentan; ansamycin derivative; salicylate sodium; humans; human; male; priority journal; endothelin receptor antagonist |
| Journal Title: | Lancet Oncology |
| Volume: | 4 |
| Issue: | 7 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2003-07-01 |
| Start Page: | 407 |
| End Page: | 414 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(03)01138-0 |
| PUBMED: | 12850191 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 25 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work